Assessment of the Ki67 labeling index

a Japanese validation ring study

Naoki Niikura, Takashi Sakatani, Nobuyuki Arima, Yasuyo Ohi, Naoko Honma, Naoki Kanomata, Kazuya Yoshida, Takayuki Kadoya, Kentaro Tamaki, Nobue Kumaki, Takayuki Iwamoto, Tomoharu Sugie, Takuya Moriya

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: A lack of consistent methods to evaluate Ki67 expression is problematic in terms of accurately predicting prognosis in breast cancer. Accordingly, this study aimed to identify the causes of discrepancies in Ki67 labeling index measurements by different observers under different conditions using breast cancer samples. Patients and methods: This Japanese study group compared and assessed immunohistochemical (IHC) analysis of the Ki67 labeling index when measured by different pathologists. Six pathologists (pathologists A–F) in Japan participated in this ring study. One hundred and ten surgical cases of estrogen receptor-positive and human epidermal growth factor receptor 2-negative invasive breast cancer treated in 2007 were identified from the breast cancer database of Tokai University Hospital and were included in this study. Results: For all 6 pathologists, the Ki67 labeling index were significantly different between grade 3 and grade 1 cases and between grade 3 and grade 2 cases, whereas the index tended to be different between grade 1 and grade 2 cases. Further, the Ki67 labeling indexes measured by the 6 pathologists were strongly correlated (ρ: 0.73–0.88). The IHC scores recorded by pathologist A were in moderate to good agreement with those recorded by the others in patients with a Ki67 labeling index of 13.25 % (κ = 0.429–0.660). The Ki67 low and high concordance rates between pathologist A and the others were 0.452–0.778 and 0.862–0.979, respectively. The most pertinent reason for discrepancy in scores seemed to be the selection of the area for counting and the quality of nuclear staining. Conclusion: The Ki67 labeling index measured by 6 pathologists without method standardization was in fair to good agreement. We plan to undertake a second ring study, pending recommendations by the international Ki67 panel.

Original languageEnglish
Pages (from-to)92-100
Number of pages9
JournalBreast Cancer
Volume23
Issue number1
DOIs
Publication statusPublished - Jan 1 2016

Fingerprint

Validation Studies
Breast Neoplasms
Pathologists
Estrogen Receptors
Japan
Databases
Staining and Labeling

Keywords

  • Breast cancer
  • Ki67
  • Proliferation
  • Ring study

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Pharmacology (medical)

Cite this

Niikura, N., Sakatani, T., Arima, N., Ohi, Y., Honma, N., Kanomata, N., ... Moriya, T. (2016). Assessment of the Ki67 labeling index: a Japanese validation ring study. Breast Cancer, 23(1), 92-100. https://doi.org/10.1007/s12282-014-0536-0

Assessment of the Ki67 labeling index : a Japanese validation ring study. / Niikura, Naoki; Sakatani, Takashi; Arima, Nobuyuki; Ohi, Yasuyo; Honma, Naoko; Kanomata, Naoki; Yoshida, Kazuya; Kadoya, Takayuki; Tamaki, Kentaro; Kumaki, Nobue; Iwamoto, Takayuki; Sugie, Tomoharu; Moriya, Takuya.

In: Breast Cancer, Vol. 23, No. 1, 01.01.2016, p. 92-100.

Research output: Contribution to journalArticle

Niikura, N, Sakatani, T, Arima, N, Ohi, Y, Honma, N, Kanomata, N, Yoshida, K, Kadoya, T, Tamaki, K, Kumaki, N, Iwamoto, T, Sugie, T & Moriya, T 2016, 'Assessment of the Ki67 labeling index: a Japanese validation ring study', Breast Cancer, vol. 23, no. 1, pp. 92-100. https://doi.org/10.1007/s12282-014-0536-0
Niikura N, Sakatani T, Arima N, Ohi Y, Honma N, Kanomata N et al. Assessment of the Ki67 labeling index: a Japanese validation ring study. Breast Cancer. 2016 Jan 1;23(1):92-100. https://doi.org/10.1007/s12282-014-0536-0
Niikura, Naoki ; Sakatani, Takashi ; Arima, Nobuyuki ; Ohi, Yasuyo ; Honma, Naoko ; Kanomata, Naoki ; Yoshida, Kazuya ; Kadoya, Takayuki ; Tamaki, Kentaro ; Kumaki, Nobue ; Iwamoto, Takayuki ; Sugie, Tomoharu ; Moriya, Takuya. / Assessment of the Ki67 labeling index : a Japanese validation ring study. In: Breast Cancer. 2016 ; Vol. 23, No. 1. pp. 92-100.
@article{910f828d35be4e7ca6b87ebc0ef83736,
title = "Assessment of the Ki67 labeling index: a Japanese validation ring study",
abstract = "Background: A lack of consistent methods to evaluate Ki67 expression is problematic in terms of accurately predicting prognosis in breast cancer. Accordingly, this study aimed to identify the causes of discrepancies in Ki67 labeling index measurements by different observers under different conditions using breast cancer samples. Patients and methods: This Japanese study group compared and assessed immunohistochemical (IHC) analysis of the Ki67 labeling index when measured by different pathologists. Six pathologists (pathologists A–F) in Japan participated in this ring study. One hundred and ten surgical cases of estrogen receptor-positive and human epidermal growth factor receptor 2-negative invasive breast cancer treated in 2007 were identified from the breast cancer database of Tokai University Hospital and were included in this study. Results: For all 6 pathologists, the Ki67 labeling index were significantly different between grade 3 and grade 1 cases and between grade 3 and grade 2 cases, whereas the index tended to be different between grade 1 and grade 2 cases. Further, the Ki67 labeling indexes measured by the 6 pathologists were strongly correlated (ρ: 0.73–0.88). The IHC scores recorded by pathologist A were in moderate to good agreement with those recorded by the others in patients with a Ki67 labeling index of 13.25 {\%} (κ = 0.429–0.660). The Ki67 low and high concordance rates between pathologist A and the others were 0.452–0.778 and 0.862–0.979, respectively. The most pertinent reason for discrepancy in scores seemed to be the selection of the area for counting and the quality of nuclear staining. Conclusion: The Ki67 labeling index measured by 6 pathologists without method standardization was in fair to good agreement. We plan to undertake a second ring study, pending recommendations by the international Ki67 panel.",
keywords = "Breast cancer, Ki67, Proliferation, Ring study",
author = "Naoki Niikura and Takashi Sakatani and Nobuyuki Arima and Yasuyo Ohi and Naoko Honma and Naoki Kanomata and Kazuya Yoshida and Takayuki Kadoya and Kentaro Tamaki and Nobue Kumaki and Takayuki Iwamoto and Tomoharu Sugie and Takuya Moriya",
year = "2016",
month = "1",
day = "1",
doi = "10.1007/s12282-014-0536-0",
language = "English",
volume = "23",
pages = "92--100",
journal = "Breast Cancer",
issn = "1340-6868",
publisher = "Springer Japan",
number = "1",

}

TY - JOUR

T1 - Assessment of the Ki67 labeling index

T2 - a Japanese validation ring study

AU - Niikura, Naoki

AU - Sakatani, Takashi

AU - Arima, Nobuyuki

AU - Ohi, Yasuyo

AU - Honma, Naoko

AU - Kanomata, Naoki

AU - Yoshida, Kazuya

AU - Kadoya, Takayuki

AU - Tamaki, Kentaro

AU - Kumaki, Nobue

AU - Iwamoto, Takayuki

AU - Sugie, Tomoharu

AU - Moriya, Takuya

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Background: A lack of consistent methods to evaluate Ki67 expression is problematic in terms of accurately predicting prognosis in breast cancer. Accordingly, this study aimed to identify the causes of discrepancies in Ki67 labeling index measurements by different observers under different conditions using breast cancer samples. Patients and methods: This Japanese study group compared and assessed immunohistochemical (IHC) analysis of the Ki67 labeling index when measured by different pathologists. Six pathologists (pathologists A–F) in Japan participated in this ring study. One hundred and ten surgical cases of estrogen receptor-positive and human epidermal growth factor receptor 2-negative invasive breast cancer treated in 2007 were identified from the breast cancer database of Tokai University Hospital and were included in this study. Results: For all 6 pathologists, the Ki67 labeling index were significantly different between grade 3 and grade 1 cases and between grade 3 and grade 2 cases, whereas the index tended to be different between grade 1 and grade 2 cases. Further, the Ki67 labeling indexes measured by the 6 pathologists were strongly correlated (ρ: 0.73–0.88). The IHC scores recorded by pathologist A were in moderate to good agreement with those recorded by the others in patients with a Ki67 labeling index of 13.25 % (κ = 0.429–0.660). The Ki67 low and high concordance rates between pathologist A and the others were 0.452–0.778 and 0.862–0.979, respectively. The most pertinent reason for discrepancy in scores seemed to be the selection of the area for counting and the quality of nuclear staining. Conclusion: The Ki67 labeling index measured by 6 pathologists without method standardization was in fair to good agreement. We plan to undertake a second ring study, pending recommendations by the international Ki67 panel.

AB - Background: A lack of consistent methods to evaluate Ki67 expression is problematic in terms of accurately predicting prognosis in breast cancer. Accordingly, this study aimed to identify the causes of discrepancies in Ki67 labeling index measurements by different observers under different conditions using breast cancer samples. Patients and methods: This Japanese study group compared and assessed immunohistochemical (IHC) analysis of the Ki67 labeling index when measured by different pathologists. Six pathologists (pathologists A–F) in Japan participated in this ring study. One hundred and ten surgical cases of estrogen receptor-positive and human epidermal growth factor receptor 2-negative invasive breast cancer treated in 2007 were identified from the breast cancer database of Tokai University Hospital and were included in this study. Results: For all 6 pathologists, the Ki67 labeling index were significantly different between grade 3 and grade 1 cases and between grade 3 and grade 2 cases, whereas the index tended to be different between grade 1 and grade 2 cases. Further, the Ki67 labeling indexes measured by the 6 pathologists were strongly correlated (ρ: 0.73–0.88). The IHC scores recorded by pathologist A were in moderate to good agreement with those recorded by the others in patients with a Ki67 labeling index of 13.25 % (κ = 0.429–0.660). The Ki67 low and high concordance rates between pathologist A and the others were 0.452–0.778 and 0.862–0.979, respectively. The most pertinent reason for discrepancy in scores seemed to be the selection of the area for counting and the quality of nuclear staining. Conclusion: The Ki67 labeling index measured by 6 pathologists without method standardization was in fair to good agreement. We plan to undertake a second ring study, pending recommendations by the international Ki67 panel.

KW - Breast cancer

KW - Ki67

KW - Proliferation

KW - Ring study

UR - http://www.scopus.com/inward/record.url?scp=84952873081&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952873081&partnerID=8YFLogxK

U2 - 10.1007/s12282-014-0536-0

DO - 10.1007/s12282-014-0536-0

M3 - Article

VL - 23

SP - 92

EP - 100

JO - Breast Cancer

JF - Breast Cancer

SN - 1340-6868

IS - 1

ER -